ASND NASDAQ
Credit Risk of going bust: lower than 83% of companies Debt: 3.0% of company value Bonds: none of note held by US funds details ▾
Total debt $502.8M against a stock market value of $16.13B.
Distance to default 10.53 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $287.9M (short-term plus half of long-term), stock volatility 38.8%; Altman Z'' 1.93. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Hellerup, CR 2900
DK
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 Ã/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bodenhoff Mads | M-Exempt | 3,000 | $110.00 | 2026-09-08 |
| Bodenhoff Mads | S-Sale | 3,000 | $270.19 | 2026-09-08 |
| Bodenhoff Mads | M-Exempt | 3,000 | $110.00 | 2026-09-08 |
| HOLTUG LARS | S-Sale | 236 | $264.13 | 2026-09-02 |
| BIENAIME JEAN JACQUE | P-Purchase | 1,100 | $245.85 | 2026-08-14 |